<DOC>
	<DOC>NCT02835976</DOC>
	<brief_summary>This Phase I study is designed to determine the excretion balance of radiocarbon, as the sum of carbon-14 (14C)-labeled TRO19622 and its 14C-metabolites, and to investigate the pharmacokinetics and metabolic profile of TRO19622 (olesoxime) in healthy participants.</brief_summary>
	<brief_title>A Study of the Excretion Balance of Radiocarbon and the Pharmacokinetics and Metabolic Profile of TRO19622 (Olesoxime)</brief_title>
	<detailed_description />
	<criteria>Body mass index (BMI) 20.0 to 28.0 kilograms per metersquared (kg/m^2) and body weight at least 60 kilograms (kg) Fitzpatrick skin type less than (&lt;) 4 Good health according to medical history, physical examination, laboratory parameters, vital signs, and 12lead electrocardiogram (ECG) Negative urine test for drugs of abuse Negative alcohol breath test Negative tests for hepatitis or human immunodeficiency virus (HIV) Use of effective contraception during and for 3 months beyond study participant, among sexually active nonvasectomized participants with females partners of childbearing potential Concomitant or recent medication use within 2 weeks prior to Day 1, except for paracetamol Use of enzymeinducing drugs within 2 months prior to Day 1 Any medical condition that may alter the pharmacokinetics of olesoxime or affect interpretation of study results Irregular bowel movements Drug addiction or alcoholism Use of nicotine products Participation in another clinical study within 12 weeks prior to Day 1 Exposure to ionizing radiation within one year prior to Day 1</criteria>
	<gender>Male</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>